Identification of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines

Identification of genetic copy number changes in glial tumors is of importance in the context of improved/refined diagnostic, prognostic procedures and therapeutic decision-making. In order to detect recurrent genomic copy number changes that might play a role in glioma pathogenesis and/or progression, we characterized 25 primary glioma cell lines including 15 non glioblastoma (non GBM) (I–III WHO grade) and 10 GBM (IV WHO grade), by array comparative genomic hybridization, using a DNA microarray comprising approx. 3500 BACs covering the entire genome with a 1 Mb resolution and additional 800 BACs covering chromosome 19 at tiling path resolution. Combined evaluation by single clone and whole chromosome analysis plus ‘moving average (MA) approach’ enabled us to confirm most of the genetic abnormalities previously identified to be associated with glioma progression, including +1q32, +7, −10, −22q, PTEN and p16 loss, and to disclose new small genomic regions, some correlating with grade malignancy. Grade I–III gliomas exclusively showed losses at 3p26 (53%), 4q13–21 (33%) and 7p15–p21 (26%), whereas only GBMs exhibited 4p16.1 losses (40%). Other recurrent imbalances, such as losses at 4p15, 5q22–q23, 6p23–25, 12p13 and gains at 11p11–q13, were shared by different glioma grades. Three intervals with peak of loss could be further refined for chromosome 10 by our MA approach. Data analysis of full-coverage chromosome 19 highlighted two main regions of copy number gain, never described before in gliomas, at 19p13.11 and 19q13.13–13.2. The well-known 19q13.3 loss of heterozygosity area in gliomas was not frequently affected in our cell lines. Genomic hotspot detection facilitated the identification of small intervals resulting in positional candidate genes such as PRDM2 (1p36.21), LRP1B (2q22.3), ADARB2 (10p15.3), BCCIP (10q26.2) and ING1 (13q34) for losses and ECT2 (3q26.3), MDK, DDB2, IG20 (11p11.2) for gains. These data increase our current knowledge about cryptic genetic changes in gliomas and may facilitate the further identification of novel genetic elements, which may provide us with molecular tools for the improved diagnostics and therapeutic decision-making in these tumors.

[1]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[2]  G. Finocchiaro,et al.  A recurrent 19q11-12 breakpoint suggested by cytogenetic and fluorescence in situ hybridization analysis of three glioblastoma cell lines. , 1999, Cancer genetics and cytogenetics.

[3]  G. Reifenberger,et al.  Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target , 2003, International journal of cancer.

[4]  R. Jenkins,et al.  Recent advances in the molecular genetics of primary gliomas , 2003, Current opinion in oncology.

[5]  K. Takahashi,et al.  cDNA cloning of a novel protein containing two zinc-finger domains that may function as a transcription factor for the human heme-oxygenase-1 gene. , 1996, European journal of biochemistry.

[6]  Zhiyuan Shen,et al.  Inhibition of G1 to S Cell Cycle Progression by BCCIPb , 2004 .

[7]  Thomas Koschny,et al.  Comparative genomic hybridization in glioma: a meta-analysis of 509 cases. , 2002, Cancer genetics and cytogenetics.

[8]  L. Recht,et al.  High-resolution genome-wide mapping of genetic alterations in human glial brain tumors. , 2005, Cancer research.

[9]  K. Aldape,et al.  Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR , 2004, Genes, chromosomes & cancer.

[10]  Ton Feuth,et al.  Array-based comparative genomic hybridization for the genomewide detection of submicroscopic chromosomal abnormalities. , 2003, American journal of human genetics.

[11]  C. Hawkins.  TRAIL and malignant glioma. , 2004, Vitamins and hormones.

[12]  E. Soeda,et al.  A sequence-ready BAC clone contig of human chromosome 10p15 spanning the loss of heterozygosity region in glioma. , 2000, Genomics.

[13]  L. Feuk,et al.  Detection of large-scale variation in the human genome , 2004, Nature Genetics.

[14]  Rolph Pfundt,et al.  Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization. , 2005, Blood.

[15]  R Fankhauser,et al.  Tumours of the nervous system. , 1974, Bulletin of the World Health Organization.

[16]  Andreas von Deimling,et al.  Impact of Genotype and Morphology on the Prognosis of Glioblastoma , 2002, Journal of neuropathology and experimental neurology.

[17]  K. Zang,et al.  Establishment and characterization of a human glioblastoma cell line with a stable karyotype and nullisomy 13. , 1985, Cancer genetics and cytogenetics.

[18]  C. Chao,et al.  Cross-Resistance to Death Ligand-Induced Apoptosis in Cisplatin-Selected HeLa Cells Associated with Overexpression of DDB2 and Subsequent Induction of cFLIP , 2005, Molecular Pharmacology.

[19]  D. Nelson,et al.  Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. , 1993, International journal of radiation oncology, biology, physics.

[20]  G. Barnett,et al.  Characterization of the 1p/19q Chromosomal Loss in Oligodendrogliomas Using Comparative Genomic Hybridization Arrays (CGHa) , 2004, Journal of neuropathology and experimental neurology.

[21]  P. Kleihues,et al.  Genetic alterations associated with the evolution and progression of astrocytic brain tumours , 2004, Virchows Archiv.

[22]  Peter Lichter,et al.  Amplification and Expression of Cyclin D Genes (CCND1 CCND2 and CCND3) in Human Malignant Gliomas , 1999, Brain pathology.

[23]  V. Ganju,et al.  Region‐specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma , 1995, Genes, chromosomes & cancer.

[24]  G. Broggi,et al.  Increasing complexity of the karyotype in 50 human gliomas. Progressive evolution and de novo occurrence of cytogenetic alterations. , 1994, Cancer genetics and cytogenetics.

[25]  R. Hammer,et al.  Normal Development and Fertility of Knockout Mice Lacking the Tumor Suppressor Gene LRP1b Suggest Functional Compensation by LRP1 , 2004, Molecular and Cellular Biology.

[26]  V P Collins,et al.  Brain tumours: classification and genes , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[27]  B. Scheithauer,et al.  Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype , 1999, Oncogene.

[28]  L. Parada,et al.  The Molecular and Genetic Basis of Neurological Tumours , 2002, Nature Reviews Cancer.

[29]  D. Bigner,et al.  Chromosomal progression of malignant human gliomas from biopsy to establishment as permanent lines in vitro. , 1987, Cancer genetics and cytogenetics.

[30]  N. Nowak,et al.  Application of bacterial artificial chromosome array-based comparative genomic hybridization and spectral karyotyping to the analysis of glioblastoma multiforme. , 2004, Cancer genetics and cytogenetics.

[31]  D. Louis,et al.  Transcript map of the 3.7-Mb D19S112-D19S246 candidate tumor suppressor region on the long arm of chromosome 19. , 2002, Cancer research.

[32]  W. Cleveland.  Robust Locally Weighted Regression and Smoothing Scatterplots , 1979 .

[33]  Zhiyuan Shen,et al.  Genomic structure of the human BCCIP gene and its expression in cancer. , 2003, Gene.

[34]  Webster K. Cavenee,et al.  Pathology and genetics of tumours of the nervous system. , 2000 .

[35]  Mark Noble,et al.  The complex identity of brain tumors: emerging concerns regarding origin, diversity and plasticity , 2004, Trends in Neurosciences.

[36]  K. Aldape,et al.  Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. , 2005, Cancer research.

[37]  M. Wolter,et al.  Absence of mutations in the putative tumor suppressor gene KLF6 in glioblastomas and meningiomas , 2004, International journal of cancer.

[38]  F. Mitelman.  ISCN 1991 : guidelines for cancer cytogenetics : supplement to An international system for human cytogenetic nomenclature : recommendations of the Standing Committee on Human Cytogenetic Nomenclature, Subcommittee on Cancer Cytogenetics , 1992 .

[39]  Kenny Q. Ye,et al.  Large-Scale Copy Number Polymorphism in the Human Genome , 2004, Science.

[40]  B. Feuerstein,et al.  Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas , 2005, Genes, chromosomes & cancer.

[41]  J. Shapiro.  Genetic alterations associated with adult diffuse astrocytic tumors. , 2002, American journal of medical genetics.

[42]  J. Veltman,et al.  Definition of a critical region on chromosome 18 for congenital aural atresia by arrayCGH. , 2003, American journal of human genetics.

[43]  S. Nelson,et al.  DNA-microarray analysis of brain cancer: molecular classification for therapy , 2004, Nature Reviews Neuroscience.

[44]  P. Wesseling,et al.  Molecular pathogenesis of oligodendroglial tumors , 2004, Journal of Neuro-Oncology.

[45]  A. von Deimling,et al.  No ING1 mutations in human brain tumours but reduced expression in high malignancy grades of astrocytoma , 2004, International journal of cancer.

[46]  R. Pfundt,et al.  Identification of oligodendroglioma specific chromosomal copy number changes in the glioblastoma MI-4 cell line by array-CGH and FISH analyses. , 2005, Cancer genetics and cytogenetics.

[47]  M. Varella‐Garcia,et al.  Establishment and characterization of a human glioblastoma multiforme cell line. , 1998, Cancer genetics and cytogenetics.

[48]  G. Finocchiaro,et al.  Mxi1 inhibits the proliferation of U87 glioma cells through down-regulation of cyclin B1 gene expression , 2002, British Journal of Cancer.

[49]  A. Silvani,et al.  Characterization of an established human, malignant, glioblastoma cell line (GBM) and its response to conventional drugs , 2005, Journal of Cancer Research and Clinical Oncology.

[50]  Sarah Barber,et al.  A set of BAC clones spanning the human genome. , 2004, Nucleic acids research.

[51]  Erwin G. Van Meir,et al.  PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. , 2005, Cancer research.

[52]  R. Moroni,et al.  The neural progenitor-restricted isoform of the MARK4 gene in 19q13.2 is upregulated in human gliomas and overexpressed in a subset of glioblastoma cell lines , 2003, Oncogene.

[53]  J. Rey,et al.  Cytogenetic follow-up from direct preparation to advanced in vitro passages of a human malignant glioma. , 1989, Cancer genetics and cytogenetics.

[54]  B. Prabhakar,et al.  IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs , 2004, Oncogene.

[55]  Yuan Yuan,et al.  Inhibition of breast and brain cancer cell growth by BCCIPα, an evolutionarily conserved nuclear protein that interacts with BRCA2 , 2001, Oncogene.

[56]  A. Montpetit,et al.  A detailed transcriptional map of the chromosome 12p12 tumour suppressor locus , 2002, European Journal of Human Genetics.

[57]  B. Roe,et al.  A novel member of the WD-repeat gene family, WDR11, maps to the 10q26 region and is disrupted by a chromosome translocation in human glioblastoma cells , 2001, Oncogene.